Abstract: The present invention relates to a process for isolating (?S,?R)-6-bromo-?-[2-(dimethylamino)ethyl]-2-methoxy-?-1-naphthalenyl-?-phenyl-3-quinolineethanol from a mixture of stereoisomeric forms of 6-bromo-?-[2-(dimethylamino)ethyl]-2-methoxy-?-1-naphthalenyl-?-phenyl-3-quinolineethanol by optical resolution with chiral 4-hydroxydinaphtho[2,1-d:1?,2?-f][1,3,2]dioxaphosphepin 4-oxide or a derivative thereof, in particular (11bR)-4-hydroxydinaphtho[2,1-d:1?,2?-f][1,3,2]dioxaphosphepin 4-oxide, as resolution agent.

Abstract: The invention relates to a device, preferably a collar, for treating areas of human or animal skin or mucous membrane with a cold atmospheric pressure plasma by creating a dielectrically hindered surface discharge, comprising at least one flexible insulating material (1), a flexible high-voltage electrode (2), a flexible dielectric (3), a flexible grounded electrode (4) and a gas supply (7), characterized in that the flexible high-voltage electrode (2) is embedded in the insulating elastomer (3), having the effect of a dielectric, and the grounded electrode (4) is applied to the elastomer surface facing the surface to be treated.

Abstract: The present invention is directed to an improved process for synthesizing phosphonic and phosphinic acid chymase inhibitor compounds.

Abstract: The present invention is directed to an improved process for synthesizing phosphonic and phosphinic acid chymase inhibitor compounds.

Abstract: Within methods and systems for computer-aided optimization of process models, defined specifications and associated release criteria (quality gates) are available for every work stage. The specifications include service documents, result features that are to be generated in a work stage, and budget details and the latest end time for a work stage. The release criteria (quality gates) can identify the results of a work stage as successful and can assess the fulfillment of a work stage. A reference for all work stages simulates the model based on a fictitious sample project, interference variables are introduced, the project implementation is simulated for each interference variable, respectively, the deviations from the reference run are automatically determined, respectively, for each interference variable, and an analysis of the influence of the release criteria (quality gates) regarding compliance with the budget and the schedule is performed based on the determined deviations from the reference run.

Abstract: The present invention relates to a process for isolating (?S,?R)-6-bromo-?-[2-(dimethylamino)ethyl]-2-methoxy-?-1-naphthalenyl-?-phenyl-3-quinolineethanol from a mixture of stereoisomeric forms of 6-bromo-?-[2-(dimethylamino)ethyl]-2-methoxy-?-1-naphthalenyl-?-phenyl-3-quinolineethanol by optical resolution with chiral 4-hydroxydinaphtho[2,1-d:1?,2?-f][1,3,2]dioxaphosphepin 4-oxide or a derivative thereof, in particular (11bR)-4-hydroxydinaphtho[2,1-d:1?,2?-f][1,3,2]dioxaphosphepin 4-oxide, as resolution agent.

Abstract: The present invention relates to a process for isolating (?S,?R)-6-bromo-?-[2-(dimethylamino)ethyl]-2-methoxy-?-1-naphthalenyl-?-phenyl-3-quinolineethanol from a mixture of stereoisomeric forms of 6-bromo-?-[2-(dimethylamino)ethyl]-2-methoxy-?-1-naphthalenyl-?-phenyl-3-quinolineethanol by optical resolution with chiral 4-hydroxydinaphtho[2,1-d:1?,2?-f][1,3,2]dioxaphosphepin 4-oxide or a derivative thereof, in particular (11bR)-4-hydroxydinaphtho[2,1-d:1?,2?-f][1,3,2]dioxaphosphepin 4-oxide, as resolution agent.

Abstract: A method and an apparatus are disclosed for detecting and evolving of a structure for storage, analysis and exchange of information data between domains and organizations. In at least one embodiment, the schema of all relevant domains of the organizations is determined on the basis of the meta-schema which includes a set of rules for generating the schema which has at least one dimension. Data of one domain can be easily used for evaluation or decision taken in other domains within the same or different organizations.

Abstract: The present invention is directed to an improved process for synthesizing phosphonic and phosphinic acid chymase inhibitor compounds.

Abstract: The present invention relates to a process for isolating (?S,?R)-6-bromo-?-[2-(dimethylamino)ethyl]-2-methoxy-?-1-naphthalenyl-?-phenyl-3-quinolineethanol from a mixture of stereoisomeric forms of 6-bromo-?-[2-(dimethylamino)ethyl]-2-methoxy-?-1-naphthalenyl-?-phenyl-3-quinolineethanol by optical resolution with chiral 4-hydroxydinaphtho[2,1-d:1?,2?-f][1,3,2]dioxaphosphepin 4-oxide or a derivative thereof, in particular (11bR)-4-hydroxydinaphtho[2,1-d:1?,2?-f][1,3,2]dioxaphosphepin 4-oxide, as resolution agent.

Abstract: N-ethyl-N-[3-(3-cyanopyrazolo[1,5-a]pyrimidine-7-yl)phenyl]acetamide (Zaleplon) can be produced by condensing 3-(N-acetyl-N-ethyl-amino)-?-oxo-phenylpropanal sodium salt with 3-amino-4-cyanopyrazole. Said sodium salt can be produced by first treating 3-acetylamino-acetophenone with an alkali metal hydroxide, in particular with powdered potassium hydroxide and then with an ethylating reagent, in particular ethyl bromide and the N-(3-acetylphenyl)-N-ethyl-acetamide that is obtained is reacted with a formic acid alkyl ester in the presence of an alkali metal alkanolate, in particular in the presence of sodium ethanolate. Zaleplon is the active ingredient of the soporific licensed under the trade name Sonata®.

Abstract: N-ethyl-N-[3-(3-cyanopyrazolo[1,5a]pyrimidine-7-yl)phenyl]acetamide (Zaleplon) can be produced by condensing 3-(N-acetyl-N-ethyl-amino)-?-oxo-phenylpropanal sodium salt with 3-amino-4-cyanopyrazole. Said sodium salt can be produced by first treating 3-acetylamino-acetophenone with an alkali metal hydroxide, in particular with powdered potassium hydroxide and then with an ethylating reagent, in particular ethyl bromide and the N-(3-acetylphenyl)-N-ethyl-acetamide that is obtained is reacted with a formic acid alkyl ester in the presence of an alkali metal alkanolate, in particular in the presence of sodium ethanolate. Zaleplon is the active ingredient of the soporific licensed under the trade name Sonata®.